Teneligliptin

Teneligliptin
Clinical data
Trade names	Tenelia
ATC code	None;
Legal status
Legal status	Approved in Japan;
Identifiers
	IUPAC name {(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone;
CAS Number	760937-92-6;
PubChem CID	11949652;
ChemSpider	10123963;
UNII	28ZHI4CF9C;
CompTox Dashboard (EPA)	DTXSID30997419 ;
Chemical and physical data
Formula	C22H30N6OS
Molar mass	426.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5;
	InChI InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1; Key:WGRQANOPCQRCME-PMACEKPBSA-N;

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[1]

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.^[2]

It is approved for use in Japan, Argentina, Korea and India.^[3]

Teneligliptin has unique J shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.^[4]

^ Kishimoto M (2013). "Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, Metabolic Syndrome and Obesity. 6: 187–95. doi:10.2147/DMSO.S35682. PMC 3650886. PMID 23671395.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ "TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy". Media & Investors. Daiichi Sankyo.
^ Bronson, Joanne; Black, Amelia; Dhar, T. G. Murali; Ellsworth, Bruce A.; Merritt, J. Robert (2013). Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012. Vol. 48. pp. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 9780124171503. {{cite book}}: |journal= ignored (help); Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T (May 2013). "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". Biochemical and Biophysical Research Communications. 434 (2): 191–6. doi:10.1016/j.bbrc.2013.03.010. PMID 23501107.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.